Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Ischemic Heart Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 187 articles: HTML format

Single Articles

April 2021
1. WANG Y
   Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
   JAMA. 2021;325:1333.
   PubMed    
   
   
   
2. OLSHANSKY B, Bhatt DL, Chung MK
   Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
   JAMA. 2021;325:1332-1333.
   PubMed    
   
   
   
3. PARK KY, Park HK, Hwang HS
   Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
   JAMA. 2021;325:1334.
   PubMed    
   
   
   
4. WELTY F, Bistrian B, Driscoll D
   Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk.
   JAMA. 2021;325:1333.
   PubMed    
   
   
   
5. NISSEN SE, Lincoff AM, Nicholls SJ
   Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk-Reply.
   JAMA. 2021;325:1334-1335.
   PubMed    
   
   
   March 2021
6. SLOMSKI A
   Polypill Plus Aspirin Effective for Cardiovascular Disease Prevention.
   JAMA. 2021;325:1135.
   PubMed    
   
   
   
7. FRIEDEN TR, Foti KE
   National Initiatives to Prevent Myocardial Infarction and Stroke.
   JAMA. 2021 Mar 12. pii: 2777651. doi: 10.1001/jama.2021.0905.
   PubMed    
   
   
   
8. YOU SC, Gupta A, Krumholz HM
   Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention-Reply.
   JAMA. 2021;325:890-891.
   PubMed    
   
   
   
9. KIM HK, Kubica J, Jeong YH
   Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention.
   JAMA. 2021;325:890.
   PubMed    
   
   
   February 2021
10. KOLTE D, Libby P, Jang IK
    New Insights Into Plaque Erosion as a Mechanism of Acute Coronary Syndromes.
    JAMA. 2021 Feb 22. pii: 2776938. doi: 10.1001/jama.2021.0069.
    PubMed    
    
    
    
11. PERAK AM, Lancki N, Kuang A, Labarthe DR, et al
    Associations of Maternal Cardiovascular Health in Pregnancy With Offspring Cardiovascular Health in Early Adolescence.
    JAMA. 2021;325:658-668.
    PubMed     Abstract available
    
    
    
12. DANIELS SR
    Maternal Cardiovascular Health: A Critical Period for Offspring Lifetime Cardiovascular Health?
    JAMA. 2021;325:630-631.
    PubMed    
    
    
    
13. DUCROCQ G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, et al
    Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
    JAMA. 2021;325:552-560.
    PubMed     Abstract available
    
    
    
14. KHATANA SAM, Venkataramani AS, Nathan AS, Dayoub EJ, et al
    Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults.
    JAMA. 2021;325:445-453.
    PubMed     Abstract available
    
    
    
15. WEEKS WB, Weinstein JN
    Economic Prosperity and Cardiovascular Mortality: Further Evidence That All Policy Is Health Policy.
    JAMA. 2021;325:439-440.
    PubMed    
    
    
    January 2021
16. LOPES RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, et al
    Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
    JAMA. 2021;325:254-264.
    PubMed     Abstract available
    
    
    December 2020
17. SLOMSKI A
    Empagliflozin Cuts Cardiovascular Deaths in Advanced Heart Failure.
    JAMA. 2020;324:2476.
    PubMed    
    
    
    
18. HARSHFIELD EL, Pennells L, Schwartz JE, Willeit P, et al
    Association Between Depressive Symptoms and Incident Cardiovascular Diseases.
    JAMA. 2020;324:2396-2405.
    PubMed     Abstract available
    
    
    
19. PATEL MM, Uyeki TM
    Influenza Vaccine for Patients With High-risk Cardiovascular Disease.
    JAMA. 2020 Dec 4. pii: 2773988. doi: 10.1001/jama.2020.23948.
    PubMed    
    
    
    
20. VARDENY O, Kim K, Udell JA, Joseph J, et al
    Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.
    JAMA. 2020 Dec 4. pii: 2773989. doi: 10.1001/jama.2020.23649.
    PubMed     Abstract available
    
    
    November 2020
21. KRIST AH, Davidson KW, Mangione CM, Barry MJ, et al
    Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2020;324:2069-2075.
    PubMed     Abstract available
    
    
    
22. O'CONNOR EA, Evans CV, Rushkin MC, Redmond N, et al
    Behavioral Counseling to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2020;324:2076-2094.
    PubMed     Abstract available
    
    
    
23. JIN J
    Counseling on Healthy Diet and Physical Activity to Prevent Cardiovascular Disease.
    JAMA. 2020;324:2114.
    PubMed    
    
    
    
24. SMILOWITZ NR, Berger JS
    Cardiovascular Risk Assessment for Noncardiac Surgery-Reply.
    JAMA. 2020;324:2106-2107.
    PubMed    
    
    
    
25. GRASSHOFF C, Magunia H
    Cardiovascular Risk Assessment for Noncardiac Surgery.
    JAMA. 2020;324:2105-2106.
    PubMed    
    
    
    
26. KHAN SS, Greenland P
    Comprehensive Cardiovascular Health Promotion for Successful Prevention of Cardiovascular Disease.
    JAMA. 2020;324:2036-2037.
    PubMed    
    
    
    
27. SHARMA G, Martin SS, Blumenthal RS
    Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events: What Matters Most: the Drug, the Dose, or the Placebo?
    JAMA. 2020 Nov 15. pii: 2773118. doi: 10.1001/jama.2020.22387.
    PubMed    
    
    
    
28. NICHOLLS SJ, Lincoff AM, Garcia M, Bash D, et al
    Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
    JAMA. 2020 Nov 15. pii: 2773120. doi: 10.1001/jama.2020.22258.
    PubMed     Abstract available
    
    
    
29. SUD M, Han L, Koh M, Austin PC, et al
    Association Between Adherence to Fractional Flow Reserve Treatment Thresholds and Major Adverse Cardiac Events in Patients With Coronary Artery Disease.
    JAMA. 2020 Nov 13. pii: 2773127. doi: 10.1001/jama.2020.22708.
    PubMed     Abstract available
    
    
    
30. BACH RG
    Physiology-Based Revascularization Decisions and Improved Clinical Outcomes Following Percutaneous Coronary Interventions.
    JAMA. 2020 Nov 13. pii: 2773126. doi: 10.1001/jama.2020.22998.
    PubMed    
    
    
    October 2020
31. SLOMSKI A
    Colchicine Reduces Cardiovascular Events in Chronic Coronary Disease.
    JAMA. 2020;324:1599.
    PubMed    
    
    
    
32. BATES ER
    Net Adverse Clinical Events With Antiplatelet Therapy in Acute Coronary Syndromes.
    JAMA. 2020;324:1613-1615.
    PubMed    
    
    
    
33. YOU SC, Rho Y, Bikdeli B, Kim J, et al
    Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    JAMA. 2020;324:1640-1650.
    PubMed     Abstract available
    
    
    August 2020
34. PEREIRA NL, Farkouh ME, So D, Lennon R, et al
    Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    JAMA. 2020;324:761-771.
    PubMed     Abstract available
    
    
    
35. MOLITERNO DJ, Smyth SS, Abdel-Latif A
    CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size Rarely Fits All.
    JAMA. 2020;324:747-749.
    PubMed    
    
    
    July 2020
36. JABBAR A, Ingoe L, Junejo S, Carey P, et al
    Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction: A Randomized Clinical Trial.
    JAMA. 2020;324:249-258.
    PubMed     Abstract available
    
    
    
37. DHRUVA SS, Mortazavi BJ, Desai NR
    Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock-Reply.
    JAMA. 2020;324:303-304.
    PubMed    
    
    
    
38. RAVN HB, Helgestad OKL, Moller JE
    Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock.
    JAMA. 2020;324:302-303.
    PubMed    
    
    
    
39. RIZZO JA, Dove H
    Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump for Cardiogenic Shock.
    JAMA. 2020;324:303.
    PubMed    
    
    
    
40. SMILOWITZ NR, Berger JS
    Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
    JAMA. 2020;324:279-290.
    PubMed     Abstract available
    
    
    
41. NISSEN SE, Bakaeen FG
    Coronary Revascularization Strategies: Making Sense of Sparse, Limited-Quality Data.
    JAMA. 2020;324:154-156.
    PubMed    
    
    
    
42. GAUDINO M, Benedetto U, Fremes S, Ballman K, et al
    Association of Radial Artery Graft vs Saphenous Vein Graft With Long-term Cardiovascular Outcomes Among Patients Undergoing Coronary Artery Bypass Grafting: A Systematic Review and Meta-analysis.
    JAMA. 2020;324:179-187.
    PubMed     Abstract available
    
    
    
43. ORKABY AR, Driver JA, Ho YL, Lu B, et al
    Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older.
    JAMA. 2020;324:68-78.
    PubMed     Abstract available
    
    
    June 2020
44. HADAYA J, Benharash P
    Extracorporeal Membrane Oxygenation.
    JAMA. 2020;323:2536.
    PubMed    
    
    
    
45. KIM BK, Hong SJ, Cho YH, Yun KH, et al
    Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    JAMA. 2020;323:2407-2416.
    PubMed     Abstract available
    
    
    
46. KURTH T, Rist PM, Ridker PM, Kotler G, et al
    Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women.
    JAMA. 2020;323:2281-2289.
    PubMed     Abstract available
    
    
    May 2020
47. HIRSCH IB, Gaudiani LM
    Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020.
    JAMA. 2020 May 22. pii: 2766597. doi: 10.1001/jama.2020.1303.
    PubMed    
    
    
    
48. CROSS SH, Mehra MR, Bhatt DL, Nasir K, et al
    Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017.
    JAMA. 2020;323:1852-1854.
    PubMed    
    
    
    April 2020
49. HONIGBERG MC, Natarajan P
    Premature Menopause and Risk for Cardiovascular Disease-Reply.
    JAMA. 2020;323:1617-1618.
    PubMed    
    
    
    
50. SCARABIN PY
    Premature Menopause and Risk for Cardiovascular Disease.
    JAMA. 2020;323:1616.
    PubMed    
    
    
    
51. ZHOU X, Tang G
    Premature Menopause and Risk for Cardiovascular Disease.
    JAMA. 2020;323:1616-1617.
    PubMed    
    
    
    
52. HAMPTON T
    After Heart Attack, Growth Factor Improves Scar Quality and Heart Function in Pig Study.
    JAMA. 2020;323:1235.
    PubMed    
    
    
    March 2020
53. PETRIE MC, Verma S, Docherty KF, Inzucchi SE, et al
    Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    JAMA. 2020 Mar 27. pii: 2763950. doi: 10.1001/jama.2020.1906.
    PubMed     Abstract available
    
    
    
54. PLUTZKY J
    Epigenetic Therapeutics for Cardiovascular Disease: Writing, Erasing, Reading, and Maybe Forgetting.
    JAMA. 2020 Mar 27. pii: 2763949. doi: 10.1001/jama.2020.3298.
    PubMed    
    
    
    
55. RAY KK, Nicholls SJ, Buhr KA, Ginsberg HN, et al
    Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
    JAMA. 2020 Mar 27. pii: 2763951. doi: 10.1001/jama.2020.3308.
    PubMed     Abstract available
    
    
    
56. ABBASI J
    Cardiovascular Corner-Stable Coronary Artery Disease, An LDL "Vaccine," and Anti-inflammatories.
    JAMA. 2020 Mar 18. pii: 2763421. doi: 10.1001/jama.2019.20983.
    PubMed    
    
    
    February 2020
57. LOPES RD, de Barros E Silva PGM, Damiani LP, Santos RHN, et al
    Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI.
    JAMA. 2020;323:787-789.
    PubMed    
    
    
    
58. THIELE H, Desch S, Freund A
    Microaxial Left Ventricular Assist Devices: In Search of an Appropriate Indication.
    JAMA. 2020;323:716-718.
    PubMed    
    
    
    
59. CAMPBELL BCV, Mitchell PJ, Churilov L, Yassi N, et al
    Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
    JAMA. 2020 Feb 20. pii: 2761799. doi: 10.1001/jama.2020.1511.
    PubMed     Abstract available
    
    
    
60. MOSLEY JD, Gupta DK, Tan J, Yao J, et al
    Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease.
    JAMA. 2020;323:627-635.
    PubMed     Abstract available
    
    
    
61. PETERS AT, Mutharasan RK
    Aspirin for Prevention of Cardiovascular Disease.
    JAMA. 2020;323:676.
    PubMed    
    
    
    
62. ELLIOTT J, Bodinier B, Bond TA, Chadeau-Hyam M, et al
    Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease.
    JAMA. 2020;323:636-645.
    PubMed     Abstract available
    
    
    
63. KHAN SS, Cooper R, Greenland P
    Do Polygenic Risk Scores Improve Patient Selection for Prevention of Coronary Artery Disease?
    JAMA. 2020;323:614-615.
    PubMed    
    
    
    
64. DHRUVA SS, Ross JS, Mortazavi BJ, Hurley NC, et al
    Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock.
    JAMA. 2020 Feb 10. pii: 2761003. doi: 10.1001/jama.2020.0254.
    PubMed     Abstract available
    
    
    January 2020
65. MCEVOY JW, Daya N, Rahman F, Hoogeveen RC, et al
    Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.
    JAMA. 2020;323:329-338.
    PubMed     Abstract available
    
    
    December 2019
66. YANG WY, Zhang ZY, Staessen JA
    Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomes-Reply.
    JAMA. 2019;322:2343-2344.
    PubMed    
    
    
    
67. HUANG Y, Kuang J, Mai W
    Blood Pressure Indexes Associated With Mortality and Cardiovascular Outcomes.
    JAMA. 2019;322:2342-2343.
    PubMed    
    
    
    November 2019
68. SLOMSKI A
    Polypill More Effective Than Usual Care for Reducing Cardiovascular Risks.
    JAMA. 2019;322:1948.
    PubMed    
    
    
    
69. HUFFMAN MD, Salam A, Patel A
    Implementation Strategies for Cardiovascular Polypills.
    JAMA. 2019 Nov 25. pii: 2756238. doi: 10.1001/jama.2019.18102.
    PubMed    
    
    
    
70. JOYNER MJ, Paneth N
    Cardiovascular Disease Prevention at a Crossroads:: Precision Medicine or Polypill?
    JAMA. 2019 Nov 25. pii: 2756239. doi: 10.1001/jama.2019.19026.
    PubMed    
    
    
    
71. BAIREY MERZ CN
    Testing for Coronary Microvascular Dysfunction.
    JAMA. 2019 Nov 18. pii: 2755842. doi: 10.1001/jama.2019.16625.
    PubMed    
    
    
    
72. WEI J, Cheng S, Merz CNB
    Coronary Microvascular Dysfunction Causing Cardiac Ischemia in Women.
    JAMA. 2019 Nov 18. pii: 2755840. doi: 10.1001/jama.2019.15736.
    PubMed    
    
    
    
73. HONIGBERG MC, Zekavat SM, Aragam K, Finneran P, et al
    Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.
    JAMA. 2019 Nov 18. pii: 2755841. doi: 10.1001/jama.2019.19191.
    PubMed     Abstract available
    
    
    
74. GOLDBERG AC, Leiter LA, Stroes ESG, Baum SJ, et al
    Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    JAMA. 2019;322:1780-1788.
    PubMed     Abstract available
    
    
    
75. MEIJERS WC, Moslehi JJ
    Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer.
    JAMA. 2019;322:1775-1776.
    PubMed    
    
    
    
76. WATANABE H, Kimura T
    1 vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention-Reply.
    JAMA. 2019;322:1715-1716.
    PubMed    
    
    
    
77. TAN WK
    One vs 12 Months of Dual Antiplatelet Therapy for Patients After Percutaneous Coronary Intervention.
    JAMA. 2019;322:1715.
    PubMed    
    
    
    October 2019
78. HAHN JY, Song YB, Gwon HC
    P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention-Reply.
    JAMA. 2019;322:1607-1608.
    PubMed    
    
    
    
79. MCCAW ZR, Wei LJ
    P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    JAMA. 2019;322:1607.
    PubMed    
    
    
    
80. MORRIS NB, Gruss F, Lempert S, English T, et al
    A Preliminary Study of the Effect of Dousing and Foot Immersion on Cardiovascular and Thermal Responses to Extreme Heat.
    JAMA. 2019;322:1411-1413.
    PubMed    
    
    
    
81. JAIN A, Davis AM
    Primary Prevention of Cardiovascular Disease.
    JAMA. 2019 Oct 4:1-3. doi: 10.1001/jama.2019.15915.
    PubMed    
    
    
    September 2019
82. WEXLER DJ
    Sulfonylureas and Cardiovascular Safety: The Final Verdict?
    JAMA. 2019 Sep 19. pii: 2751396. doi: 10.1001/jama.2019.14533.
    PubMed    
    
    
    
83. ROUMIE CL, Chipman J, Min JY, Hackstadt AJ, et al
    Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function.
    JAMA. 2019 Sep 19:1-11. doi: 10.1001/jama.2019.13206.
    PubMed     Abstract available
    
    
    
84. ROSENSTOCK J, Kahn SE, Johansen OE, Zinman B, et al
    Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
    JAMA. 2019 Sep 19. pii: 2751398. doi: 10.1001/jama.2019.13772.
    PubMed     Abstract available
    
    
    
85. ABBASI J
    Cardiovascular Corner: Prescription Omega-3s, Stroke Rehab, and Statins After Age 75.
    JAMA. 2019 Sep 11. pii: 2751407. doi: 10.1001/jama.2019.14485.
    PubMed    
    
    
    
86. FERENCE BA, Bhatt DL, Catapano AL, Packard CJ, et al
    Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease.
    JAMA. 2019 Sep 2. pii: 2749533. doi: 10.1001/jama.2019.14120.
    PubMed     Abstract available
    
    
    
87. AMINIAN A, Zajichek A, Arterburn DE, Wolski KE, et al
    Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity.
    JAMA. 2019 Sep 2. pii: 2749478. doi: 10.1001/jama.2019.14231.
    PubMed     Abstract available
    
    
    August 2019
88. DUNCAN MS, Freiberg MS, Greevy RA Jr, Kundu S, et al
    Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease.
    JAMA. 2019;322:642-650.
    PubMed     Abstract available
    
    
    
89. COLE TB
    Smoking Cessation and Reduction of Cardiovascular Disease Risk.
    JAMA. 2019;322:651.
    PubMed    
    
    
    
90. YANG WY, Melgarejo JD, Thijs L, Zhang ZY, et al
    Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes.
    JAMA. 2019;322:409-420.
    PubMed     Abstract available
    
    
    
91. ZHONG VW, Van Horn L, Allen NB
    Dietary Cholesterol or Egg Consumption and Cardiovascular Outcomes-Reply.
    JAMA. 2019;322:467.
    PubMed    
    
    
    
92. KEYSERLING TC, Berkowitz SA, Samuel-Hodge CD
    Dietary Cholesterol or Egg Consumption and Cardiovascular Outcomes.
    JAMA. 2019;322:466-467.
    PubMed    
    
    
    July 2019
93. JAHAN R, Saver JL, Schwamm LH, Fonarow GC, et al
    Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice.
    JAMA. 2019;322:252-263.
    PubMed     Abstract available
    
    
    June 2019
94. HAHN JY, Song YB, Oh JH, Chun WJ, et al
    Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    JAMA. 2019;321:2428-2437.
    PubMed     Abstract available
    
    
    
95. WATANABE H, Domei T, Morimoto T, Natsuaki M, et al
    Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    JAMA. 2019;321:2414-2427.
    PubMed     Abstract available
    
    
    
96. ABBASI J
    Cardiovascular Corner: Low Lipids, Metformin, and Plant-Based Diets.
    JAMA. 2019 Jun 12. pii: 2736162. doi: 10.1001/jama.2019.6544.
    PubMed    
    
    
    
97. ZHENG SL, Roddick AJ
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply.
    JAMA. 2019;321:2244-2245.
    PubMed    
    
    
    
98. SHAH R
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
    JAMA. 2019;321:2244.
    PubMed    
    
    
    
99. SYN NL, Wee IJY
    Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
    JAMA. 2019;321:2243-2244.
    PubMed    
    
    
    May 2019
100. BERRY C, McCartney PJ, Maznyczka AM
     Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction-Reply.
     JAMA. 2019;321:2033-2034.
     PubMed    
     
     
     
101. ALKHALIL M
     Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction.
     JAMA. 2019;321:2032-2033.
     PubMed    
     
     
     
102. SEZER M, Umman S
     Fibrinolytic Therapy to Reduce Microvascular Obstruction After Myocardial Infarction.
     JAMA. 2019;321:2032.
     PubMed    
     
     
     
103. CHAN MTV, Wang CY, Seet E, Tam S, et al
     Association of Unrecognized Obstructive Sleep Apnea With Postoperative Cardiovascular Events in Patients Undergoing Major Noncardiac Surgery.
     JAMA. 2019;321:1788-1798.
     PubMed     Abstract available
     
     
     
104. AUCKLEY D, Memtsoudis S
     Unrecognized Obstructive Sleep Apnea and Postoperative Cardiovascular Complications: A Wake-up Call.
     JAMA. 2019;321:1774-1776.
     PubMed    
     
     
     
105. WISE RA, Chapman KR, Scirica BM, Bhatt DL, et al
     Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.
     JAMA. 2019;321:1693-1701.
     PubMed     Abstract available
     
     
     
106. 
     Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes.
     JAMA. 2019;321:1720-1721.
     PubMed    
     
     
     April 2019
107. GREGG EW, Hora I, Benoit SR
     Resurgence in Diabetes-Related Complications.
     JAMA. 2019 Apr 15. pii: 2730953. doi: 10.1001/jama.2019.3471.
     PubMed    
     
     
     
108. YANO Y, Muntner P, Lloyd-Jones D
     Hypertension in Young Adults and Subsequent Cardiovascular Disease-Reply.
     JAMA. 2019;321:1310-1311.
     PubMed    
     
     
     
109. DE KOUCHKOVSKY I, Mayfield J, Kohlwes J
     Hypertension in Young Adults and Subsequent Cardiovascular Disease.
     JAMA. 2019;321:1310.
     PubMed    
     
     
     March 2019
110. ZHONG VW, Van Horn L, Cornelis MC, Wilkins JT, et al
     Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality.
     JAMA. 2019;321:1081-1095.
     PubMed     Abstract available
     
     
     
111. BONOW RO, Braunwald E
     The Evidence Supporting Cardiovascular Guidelines: Is There Evidence of Progress in the Last Decade?
     JAMA. 2019;321:1053-1054.
     PubMed    
     
     
     
112. ECKEL RH
     Reconsidering the Importance of the Association of Egg Consumption and Dietary Cholesterol With Cardiovascular Disease Risk.
     JAMA. 2019;321:1055-1056.
     PubMed    
     
     
     February 2019
113. HANEUSE S, VanderWeele TJ, Arterburn D
     Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies.
     JAMA. 2019;321:602-603.
     PubMed    
     
     
     January 2019
114. FERENCE BA, Kastelein JJP, Ray KK, Ginsberg HN, et al
     Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
     JAMA. 2019;321:364-373.
     PubMed     Abstract available
     
     
     
115. NAVAR AM
     The Evolving Story of Triglycerides and Coronary Heart Disease Risk.
     JAMA. 2019;321:347-349.
     PubMed    
     
     
     
116. ZHENG SL, Roddick AJ
     Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
     JAMA. 2019;321:277-287.
     PubMed     Abstract available
     
     
     
117. MCCARTNEY PJ, Eteiba H, Maznyczka AM, McEntegart M, et al
     Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial.
     JAMA. 2019;321:56-68.
     PubMed     Abstract available
     
     
     
118. WANG TY, Kaltenbach LA, Cannon CP, Fonarow GC, et al
     Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.
     JAMA. 2019;321:44-55.
     PubMed     Abstract available
     
     
     
119. JACKEVICIUS CA, Ko DT
     Medication Co-payment Vouchers, Adherence With Antiplatelet Therapy, and Adverse Cardiovascular Events After Myocardial Infarction.
     JAMA. 2019;321:37-39.
     PubMed    
     
     
     December 2018
120. LOTTA LA, Wittemans LBL, Zuber V, Stewart ID, et al
     Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors.
     JAMA. 2018;320:2553-2563.
     PubMed     Abstract available
     
     
     
121. WADHERA RK, Joynt Maddox KE, Wasfy JH, Haneuse S, et al
     Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia.
     JAMA. 2018;320:2542-2552.
     PubMed     Abstract available
     
     
     
122. FONAROW GC
     Unintended Harm Associated With the Hospital Readmissions Reduction Program.
     JAMA. 2018;320:2539-2541.
     PubMed    
     
     
     
123. SAMIERI C, Empana JP
     Cardiovascular Health and Cognitive Decline-Reply.
     JAMA. 2018;320:2483-2484.
     PubMed    
     
     
     
124. HOWLAND RH
     Cardiovascular Health and Cognitive Decline.
     JAMA. 2018;320:2483.
     PubMed    
     
     
     November 2018
125. KIM JM, Stewart R, Yoon JS
     Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome-Reply.
     JAMA. 2018;320:2152-2153.
     PubMed    
     
     
     
126. RUST G
     Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
     JAMA. 2018;320:2152.
     PubMed    
     
     
     
127. ZIMMERMANN FM, El Farissi M, Tonino PAL
     Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
     JAMA. 2018;320:2151-2152.
     PubMed    
     
     
     
128. THOMBS BD, Ziegelstein RC
     Cardiac Outcomes After Treatment for Depression in Patients With Acute Coronary Syndrome.
     JAMA. 2018;320:2151.
     PubMed    
     
     
     
129. ROSENSTOCK J, Perkovic V, Johansen OE, Cooper ME, et al
     Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
     JAMA. 2018 Nov 9. pii: 2714646. doi: 10.1001/jama.2018.18269.
     PubMed     Abstract available
     
     
     
130. VAN SLOTEN TT, Tafflet M, Perier MC, Dugravot A, et al
     Association of Change in Cardiovascular Risk Factors With Incident Cardiovascular Events.
     JAMA. 2018;320:1793-1804.
     PubMed     Abstract available
     
     
     
131. SON JS, Choi S, Kim K, Kim SM, et al
     Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events.
     JAMA. 2018;320:1783-1792.
     PubMed     Abstract available
     
     
     
132. YANO Y, Reis JP, Colangelo LA, Shimbo D, et al
     Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life.
     JAMA. 2018;320:1774-1782.
     PubMed     Abstract available
     
     
     
133. VASAN RS
     High Blood Pressure in Young Adulthood and Risk of Premature Cardiovascular Disease: Calibrating Treatment Benefits to Potential Harm.
     JAMA. 2018;320:1760-1763.
     PubMed    
     
     
     October 2018
134. SLOMSKI A
     No Cardiovascular Protection From Omega-3 Fatty Acids.
     JAMA. 2018;320:1631.
     PubMed    
     
     
     
135. ABBASI J
     To Prevent Cardiovascular Disease, Pay Attention to Pregnancy Complications.
     JAMA. 2018 Oct 17. pii: 2708197. doi: 10.1001/jama.2018.14645.
     PubMed    
     
     
     
136. VOELKER R
     Device Approved to Seal Coronary Artery Perforations.
     JAMA. 2018;320:1528.
     PubMed    
     
     
     
137. FISHER DP, Johnson E, Haneuse S, Arterburn D, et al
     Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity.
     JAMA. 2018;320:1570-1582.
     PubMed     Abstract available
     
     
     
138. ABBASI J
     Researchers Test New Techniques to Rule Out and Predict Heart Attacks.
     JAMA. 2018;320:1425.
     PubMed    
     
     
     September 2018
139. BHATT DL
     Fractional Flow Reserve Measurement for the Physiological Assessment of Coronary Artery Stenosis Severity.
     JAMA. 2018;320:1275-1276.
     PubMed    
     
     
     
140. FRIEDRICH MJ
     Cardiovascular Disease in India.
     JAMA. 2018;320:1097.
     PubMed    
     
     
     
141. ZHU Y, Zhao Q
     Antiplatelet Therapy After Coronary Artery Bypass Grafting-Reply.
     JAMA. 2018;320:1036-1037.
     PubMed    
     
     
     
142. SHAH R, Hesterberg K
     Antiplatelet Therapy After Coronary Artery Bypass Grafting.
     JAMA. 2018;320:1035.
     PubMed    
     
     
     
143. MORI M, Geirsson A
     Antiplatelet Therapy After Coronary Artery Bypass Grafting.
     JAMA. 2018;320:1035-1036.
     PubMed    
     
     
     
144. WRIGHT JS, Wall HK, Ritchey MD
     Million Hearts 2022: Small Steps Are Needed for Cardiovascular Disease Prevention.
     JAMA. 2018 Sep 6. pii: 2702070. doi: 10.1001/jama.2018.13326.
     PubMed    
     
     
     August 2018
145. WILLIAMSON W, Lewandowski AJ, Forkert ND, Griffanti L, et al
     Association of Cardiovascular Risk Factors With MRI Indices of Cerebrovascular Structure and Function and White Matter Hyperintensities in Young Adults.
     JAMA. 2018;320:665-673.
     PubMed     Abstract available
     
     
     
146. SAMIERI C, Perier MC, Gaye B, Proust-Lima C, et al
     Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia.
     JAMA. 2018;320:657-664.
     PubMed     Abstract available
     
     
     
147. SAVER JL, Cushman M
     Striving for Ideal Cardiovascular and Brain Health: It Is Never Too Early or Too Late.
     JAMA. 2018;320:645-647.
     PubMed    
     
     
     July 2018
148. DONADINI MP, Bellesini M, Squizzato A
     Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
     JAMA. 2018 Jul 26. pii: 2695067. doi: 10.1001/jama.2018.9641.
     PubMed     Abstract available
     
     
     
149. KIM JM, Stewart R, Lee YS, Lee HJ, et al
     Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
     JAMA. 2018;320:350-358.
     PubMed     Abstract available
     
     
     
150. RUBIN R
     Red Meat Allergy Associated With Coronary Artery Plaque.
     JAMA. 2018;320:331.
     PubMed    
     
     
     
151. JIN J
     Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors.
     JAMA. 2018;320:316.
     PubMed    
     
     
     
152. WILKINS JT, Lloyd-Jones DM
     USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors: Finding the Right Tests for the Right Patients.
     JAMA. 2018 Jul 10. pii: 2687223. doi: 10.1001/jama.2018.9346.
     PubMed    
     
     
     
153. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
     Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement.
     JAMA. 2018;320:177-183.
     PubMed     Abstract available
     
     
     
154. LIN JS, Evans CV, Johnson E, Redmond N, et al
     Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
     JAMA. 2018 Jul 10. pii: 2687224. doi: 10.1001/jama.2018.4242.
     PubMed     Abstract available
     
     
     
155. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
     Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement.
     JAMA. 2018 Jul 10. pii: 2687225. doi: 10.1001/jama.2018.8359.
     PubMed     Abstract available
     
     
     June 2018
156. SELAK V, Kerr A, Poppe K, Wu B, et al
     Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
     JAMA. 2018;319:2507-2520.
     PubMed     Abstract available
     
     
     
157. JONAS DE, Reddy S, Middleton JC, Barclay C, et al
     Screening for Cardiovascular Disease Risk With Resting or Exercise Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force.
     JAMA. 2018;319:2315-2328.
     PubMed     Abstract available
     
     
     
158. CURRY SJ, Krist AH, Owens DK, Barry MJ, et al
     Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement.
     JAMA. 2018;319:2308-2314.
     PubMed     Abstract available
     
     
     
159. JIN J
     Screening for Cardiovascular Disease Risk With ECG.
     JAMA. 2018;319:2346.
     PubMed    
     
     
     
160. MCCARTHY CP, Vaduganathan M, Januzzi JL Jr
     Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment.
     JAMA. 2018 Jun 11. pii: 2684931. doi: 10.1001/jama.2018.7125.
     PubMed    
     
     
     
161. MERCHANT FM, Dickert NW Jr, Howard DH
     Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests.
     JAMA. 2018 Jun 4. pii: 2683805. doi: 10.1001/jama.2018.6617.
     PubMed    
     
     
     May 2018
162. BHATT DL
     Percutaneous Coronary Intervention in 2018.
     JAMA. 2018;319:2127-2128.
     PubMed    
     
     
     
163. ABBASI J
     Another Nail in the Coffin for Fish Oil Supplements.
     JAMA. 2018;319:1851-1852.
     PubMed    
     
     
     April 2018
164. ZHAO Q, Zhu Y, Xu Z, Cheng Z, et al
     Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
     JAMA. 2018;319:1677-1686.
     PubMed     Abstract available
     
     
     
165. ALEXANDER JH
     Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes?
     JAMA. 2018;319:1661-1662.
     PubMed    
     
     
     
166. NAVARESE EP, Robinson JG, Kowalewski M, Kolodziejczak M, et al
     Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
     JAMA. 2018;319:1566-1579.
     PubMed     Abstract available
     
     
     
167. ABBASI J
     Using Heart Pump Data to Manage Cardiogenic Shock.
     JAMA. 2018;319:1427.
     PubMed    
     
     
     
168. YU K, Qiu G, Chan KH, Lam KH, et al
     Association of Solid Fuel Use With Risk of Cardiovascular and All-Cause Mortality in Rural China.
     JAMA. 2018;319:1351-1361.
     PubMed     Abstract available
     
     
     March 2018
169. GUPTA A, Das SR, Pandey A
     beta-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
     JAMA. 2018;319:1269-1270.
     PubMed    
     
     
     
170. BERWANGER O, Santucci EV, de Barros E Silva PGM, Jesuino IA, et al
     Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.
     JAMA. 2018 Mar 11. pii: 2675023. doi: 10.1001/jama.2018.2444.
     PubMed     Abstract available
     
     
     
171. NICHOLLS SJ, Psaltis PJ
     Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough?
     JAMA. 2018 Mar 11. pii: 2675022. doi: 10.1001/jama.2018.2426.
     PubMed    
     
     
     
172. ABBASI J
     Do All Patients Need beta-Blockers After a Heart Attack?
     JAMA. 2018;319:853-855.
     PubMed    
     
     
     February 2018
173. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
     Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.
     JAMA. 2018;319:567-578.
     PubMed     Abstract available
     
     
     January 2018
174. WADHERA RK, Yeh RW, Joynt Maddox KE
     The Rise and Fall of Mandatory Cardiac Bundled Payments.
     JAMA. 2018;319:335-336.
     PubMed    
     
     
     
175. KENNEDY AB, Lavie CJ, Blair SN
     Fitness or Fatness: Which Is More Important?
     JAMA. 2018;319:231-232.
     PubMed    
     
     
     December 2017
176. GREENLAND P
     Cardiovascular Guideline Skepticism vs Lifestyle Realism?
     JAMA. 2017 Dec 14. pii: 2666625. doi: 10.1001/jama.2017.19675.
     PubMed    
     
     
     November 2017
177. SLOMSKI A
     Evolocumab Reduces Cardiovascular Risk Regardless of Diabetes Status.
     JAMA. 2017;318:1968.
     PubMed    
     
     
     
178. EMDIN CA, Khera AV, Kathiresan S
     Mendelian Randomization.
     JAMA. 2017;318:1925-1926.
     PubMed    
     
     
     
179. IRONY TZ
     The "Utility" in Composite Outcome Measures: Measuring What Is Important to Patients.
     JAMA. 2017;318:1820-1821.
     PubMed    
     
     
     
180. CHAPMAN AR, Lee KK, McAllister DA, Cullen L, et al
     Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.
     JAMA. 2017 Nov 11. doi: 10.1001/jama.2017.17488.
     PubMed     Abstract available
     
     
     October 2017
181. ABBASI J
     Could a New Method to Detect Coronary Inflammation Prevent Heart Attacks?
     JAMA. 2017;318:1527-1528.
     PubMed    
     
     
     September 2017
182. WADHERA RK, Bhatt DL
     Taking the "Public" Out of Public Reporting of Percutaneous Coronary Intervention.
     JAMA. 2017 Sep 28. doi: 10.1001/jama.2017.12087.
     PubMed    
     
     
     
183. LICHTMAN JH, Jones MR, Leifheit EC, Sheffet AJ, et al
     Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014.
     JAMA. 2017;318:1035-1046.
     PubMed     Abstract available
     
     
     
184. BARNARD ND, Willett WC, Ding EL
     The Misuse of Meta-analysis in Nutrition Research.
     JAMA. 2017 Sep 18. doi: 10.1001/jama.2017.12083.
     PubMed    
     
     
     
185. DEVEREAUX PJ, Biccard BM, Chan MTV
     High-Sensitivity Troponin Levels, Ischemia, and Mortality-Reply.
     JAMA. 2017;318:865.
     PubMed    
     
     
     
186. SMILOWITZ NR
     High-Sensitivity Troponin Levels, Ischemia, and Mortality.
     JAMA. 2017;318:864-865.
     PubMed    
     
     
     August 2017
187. KRUMHOLZ HM
     Treatment of Cholesterol in 2017.
     JAMA. 2017;318:417-418.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: